-
Sector Analysis
![]()
Hepatitis B Virus (HBV) Therapeutics – Current and Future Players
GlobalData has released its pharma report, “Hepatitis B Virus (HBV) Therapeutics - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HBV Market. The report identifies and analyses the key companies shaping and driving the global HBV market. The report provides insight into the competitive HBV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary...
-
Analyst Opinions
![]()
Dietary Supplements in an Age of Personalized Nutrition ; How the trend towards personalized health will impact the dietary supplements market
• Personalized nutrition offers manufacturers the chance to develop an ongoing relationship with consumers rather than a single transactional approach. This benefits both suppliers, who can build a base of loyal customers, and consumers, who gain a personalized and dedicated service. • Although the growth of the global market for vitamins, minerals, and supplements has slowed in recent years, the personalized nutrition trend will push growth at a CAGR of 6.5% from an estimated total value of $93bn in 2015 to $127bn...
-
Sector Analysis
![]()
Consumer and Market Insights: Suncare in Russia
The Suncare market in Russia is one of the fastest growing in Europe. The Sun Protection category accounts for the majority sales in the overall Suncare market and will register fastest growth during 2015-2020 followed by the After-Sun category.
-
Sector Analysis
![]()
OpportunityAnalyzer: Vasculitis – Opportunity Analysis and Forecast to 2024
Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behçet's disease (BD). In 2014, there were 137,603 and 82,501 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan),...
-
Sector Analysis
![]()
OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2024
The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists...
-
Sector Analysis
![]()
Immuno-Oncology Strategic Insight: Multi-Indication and Market Size Analysis
GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024. The highest-selling IO drugs by 2024 will be Opdivo and Keytruda, both PD-1 inhibitors, with sales of approximately $10 billion...
-
Sector Analysis
![]()
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecast to 2025
The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF – Roche's Esbriet and Boehringer Ingelheim's Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it was approved for use in Europe, a full four years before rival Ofev. However, both gained approval into the largest IPF market of the US on the same day in October 2014. The top-selling drug in IPF in value terms...
-
Sector Analysis
![]()
OpportunityAnalyzer: Myelofibrosis – Opportunity Analysis and Forecasts to 2025
Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is only one approved drug, Incyte/Novartis' Jakafi (ruxolitinib), for the treatment of MF, and other conventional therapies used in MF are off-label. However, none of these drugs are curative, and the only potentially curative intervention is allogeneic stem cell transplant (allo-SCT), which is available to a very small percentage of eligible patients because of the high risk of morbidity and mortality. Therefore, there is...
-
Sector Analysis
![]()
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths...
-
Sector Analysis
![]()
PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025
The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the...
-
Sector Analysis
![]()
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Product Insights
![]()
Influenza B Infections Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Influenza B Infections Global Clinical Trials Review, H1, 2016" provides an overview of Influenza B Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Influenza B Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
![]()
Influenza A Infections Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Influenza A Infections Global Clinical Trials Review, H1, 2016" provides an overview of Influenza A Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Influenza A Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
![]()
OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence the outcomes and treatment decisions. Patients diagnosed with indolent NHLs (follicular lymphoma [FL] or marginal zone lymphoma [MZL]) can achieve a median survival of 10 to 20 years, and relative...
-
Product Insights
![]()
Hidradenitis Suppurativa Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Hidradenitis Suppurativa Global Clinical Trials Review, H1, 2016" provides an overview of Hidradenitis Suppurativa clinical trials scenario. This report provides top line data relating to the clinical trials on Hidradenitis Suppurativa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
![]()
Retinal Vein Occlusion Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Retinal Vein Occlusion Global Clinical Trials Review, H1, 2016" provides an overview of Retinal Vein Occlusion clinical trials scenario. This report provides top line data relating to the clinical trials on Retinal Vein Occlusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
![]()
Sicca Syndrome (Sjogren) Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Sicca Syndrome (Sjogren) Global Clinical Trials Review, H1, 2016" provides an overview of Sicca Syndrome (Sjogren) clinical trials scenario. This report provides top line data relating to the clinical trials on Sicca Syndrome (Sjogren). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
![]()
Thrombophilia Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Thrombophilia Global Clinical Trials Review, H1, 2016" provides an overview of Thrombophilia clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombophilia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
![]()
Cardiovascular Inflammation Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Cardiovascular Inflammation Global Clinical Trials Review, H1, 2016" provides an overview of Cardiovascular Inflammation clinical trials scenario. This report provides top line data relating to the clinical trials on Cardiovascular Inflammation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
![]()
Liver Fibrosis Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Liver Fibrosis Global Clinical Trials Review, H1, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.